6 results on '"Tejada-Strop A"'
Number of results to display per page
Search Results
2. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel
- Author
-
Lester, Sandra N., primary, Stumpf, Megan, additional, Freeman, Brandi D., additional, Mills, Lisa, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Jia, Tao, additional, Desai, Rita, additional, Browning, Peter, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Chen, Alexander, additional, David, Ebenezer, additional, Manitis, Panagiotis, additional, Tatum, Heather, additional, Qin, Yunlong, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Tejada-Strop, Alexandra, additional, Chatterjee, Payel, additional, Shrivastava-Ranjan, Punya, additional, Jenks, M. Harley, additional, McMullan, Laura K., additional, Flint, Mike, additional, Spiropoulou, Christina F., additional, Niemeyer, Glenn P., additional, Werner, Bonnie J., additional, Bean, Christopher J., additional, Johnson, Jeffrey A., additional, Hoffmaster, Alex R., additional, Satheshkumar, Panayampalli S., additional, Schuh, Amy J., additional, Owen, S. Michele, additional, and Thornburg, Natalie J., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel
- Author
-
Sandra N. Lester, Megan Stumpf, Brandi D. Freeman, Lisa Mills, Jarad Schiffer, Vera Semenova, Tao Jia, Rita Desai, Peter Browning, Bailey Alston, Muyiwa Ategbole, Shanna Bolcen, Alexander Chen, Ebenezer David, Panagiotis Manitis, Heather Tatum, Yunlong Qin, Briana Zellner, Jan Drobeniuc, Alexandra Tejada-Strop, Payel Chatterjee, Punya Shrivastava-Ranjan, M. Harley Jenks, Laura K. McMullan, Mike Flint, Christina F. Spiropoulou, Glenn P. Niemeyer, Bonnie J. Werner, Christopher J. Bean, Jeffrey A. Johnson, Alex R. Hoffmaster, Panayampalli S. Satheshkumar, Amy J. Schuh, S. Michele Owen, and Natalie J. Thornburg
- Abstract
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (RT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of RT-PCR confirmed COVID-19 patients’ sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4%-96.6%. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698-0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies.
- Published
- 2022
- Full Text
- View/download PDF
4. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel
- Author
-
Lester, Sandra N., primary, Stumpf, Megan, additional, Freeman, Brandi D., additional, Mills, Lisa, additional, Schiffer, Jarad, additional, Semenova, Vera, additional, Jia, Tao, additional, Desai, Rita, additional, Browning, Peter, additional, Alston, Bailey, additional, Ategbole, Muyiwa, additional, Bolcen, Shanna, additional, Chen, Alexander, additional, David, Ebenezer, additional, Manitis, Panagiotis, additional, Tatum, Heather, additional, Qin, Yunlong, additional, Zellner, Briana, additional, Drobeniuc, Jan, additional, Tejada-Strop, Alexandra, additional, Chatterjee, Payel, additional, Shrivastava-Ranjan, Punya, additional, Jenks, M. Harley, additional, McMullan, Laura K., additional, Flint, Mike, additional, Spiropoulou, Christina F., additional, Niemeyer, Glenn P., additional, Werner, Bonnie J., additional, Bean, Christopher J., additional, Johnson, Jeffrey A., additional, Hoffmaster, Alex R., additional, Satheshkumar, Panayampalli S., additional, Schuh, Amy J., additional, Owen, S. Michele, additional, and Thornburg, Natalie J., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Molecular epidemiology of hepatitis B virus infection in Tanzania
- Author
-
Michael A. Purdy, Guo-liang Xia, Hong Thai, Regina Kutaga, Michael Dillon, David S. Campo, Gilberto Vaughan, Saleem Kamili, Sridhar V. Basavaraju, Lilia Ganova-Raeva, Joseph C. Forbi, Bakary Drammeh, Daniel McGovern, Yulin Lin, Dunstan Haule, Alexandra Tejada-Strop, and Yury Khudyakov
- Subjects
0301 basic medicine ,Hepatitis B virus ,Molecular epidemiology ,Phylogenetic tree ,virus diseases ,Biology ,Disease cluster ,biology.organism_classification ,medicine.disease_cause ,Virology ,digestive system diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Tanzania ,Genotype ,Immunology ,Hbv genotype ,medicine ,030212 general & internal medicine ,Posterior density - Abstract
Despite the significant public health problems associated with hepatitis B virus (HBV) in sub-Saharan Africa, many countries in this region do not have systematic HBV surveillance or genetic information on HBV circulating locally. Here, we report on the genetic characterization of 772 HBV strains from Tanzania. Phylogenetic analysis of the S-gene sequences showed prevalence of HBV genotype A (HBV/A, n=671, 86.9 %), followed by genotypes D (HBV/D, n=95, 12.3 %) and E (HBV/E, n=6, 0.8 %). All HBV/A sequences were further classified into subtype A1, while the HBV/D sequences were assigned to a new cluster. Among the Tanzanian sequences, 84 % of HBV/A1 and 94 % of HBV/D were unique. The Tanzanian and global HBV/A1 sequences were compared and were completely intermixed in the phylogenetic tree, with the Tanzanian sequences frequently generating long terminal branches, indicating a long history of HBV/A1 infections in the country. The time to the most recent common ancestor was estimated to be 188 years ago [95 % highest posterior density (HPD): 132 to 265 years] for HBV/A1 and 127 years ago (95 % HPD: 79 to 192 years) for HBV/D. The Bayesian skyline plot showed that the number of transmissions ‘exploded’ exponentially between 1960–1970 for HBV/A1 and 1970–1990 for HBV/D, with the effective population of HBV/A1 having expanded twice as much as that of HBV/D. The data suggest that Tanzania is at least a part of the geographic origin of the HBV/A1 subtype. A recent increase in the transmission rate and significant HBV genetic diversity should be taken into consideration when devising public health interventions to control HBV infections in Tanzania.
- Published
- 2017
- Full Text
- View/download PDF
6. Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel.
- Author
-
Lester SN, Stumpf M, Freeman BD, Mills L, Schiffer J, Semenova V, Jia T, Desai R, Browning P, Alston B, Ategbole M, Bolcen S, Chen A, David E, Manitis P, Tatum H, Qin Y, Zellner B, Drobeniuc J, Tejada-Strop A, Chatterjee P, Shrivastava-Ranjan P, Jenks MH, McMullan LK, Flint M, Spiropoulou CF, Niemeyer GP, Werner BJ, Bean CJ, Johnson JA, Hoffmaster AR, Satheshkumar PS, Schuh AJ, Owen SM, and Thornburg NJ
- Abstract
Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (rRT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of rRT-PCR confirmed COVID-19 patients' sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4-96.6 %. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698 to 0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies., Competing Interests: ‘The author(s) declare that there are no conflicts of interest’. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Names of specific vendors, manufacturers, or products are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention or the US Department of Health and Human Services.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.